FDA Approves Cangrelor (Kengreal) for PCIFDA Approves Cangrelor (Kengreal) for PCI

The approval in the PCI setting is based on data from CHAMPION-PHOENIX, where cangrelor reduced the risk of thrombotic events compared with patients treated clopidogrel. FDA Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news